Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- A brief history of antibodies
- Antibody structure
- The rise of recombinant monoclonal antibodies
- The dawn of antibody engineering (1)
- The dawn of antibody engineering (2)
- Humanization
- Antibody fragments (1)
- Antibody fragments (2)
- FcRn mediated recycling
- Enhancing half-life
- Mechanisms of action
- Attenuating Fc effector function (1)
- Enhancing Fc effector function (2)
- Glycoengineering
- Bispecifics
- Heavy chain heterodimerization
- Appended bispecifics
- Dual-targeting in one molecule (1)
- Dual-targeting in one molecule (2)
- Solving the light chain pairing problem
- CD3 engaging bispecifics
- An explosion of antibody formats
- Antibody drug conjugates (ADCs)
- Fc fusion proteins
- Immunokines
- FDA antibody approvals up to 2017
- Future developments
- Thank you for listening!
Topics Covered
- Introduction to antibodies and their use in therapy
- Antibody structure and function
- Antibody engineering
- Humanization
- Antibody fragments
- Fc engineering
- Half-life extension
- Modulation of Fc effector function
- Glycoengineering
- Bispecific antibodies
- Antibody drug conjugates
- Fc fusion proteins
- Immunokines
- Future developments in antibody engineering
Links
Series:
- The Immune System - Key Concepts and Questions
- Monoclonal Antibodies as Therapeutic Agents
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Wilkinson, I. (2024, September 16). Antibody engineering: beginnings to bispecifics and beyond [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 7, 2024, from https://doi.org/10.69645/XNTD7657.Export Citation (RIS)
Publication History
Financial Disclosures
- Ian Wilkinson is an empolyee of Absolute Antibody who provide services to the bio-pharma sector.
Other Talks in the Series: The Immune System - Key Concepts and Questions
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. I'm Ian Wilkinson,
the Chief Scientific Officer at Absolute Antibody,
a contract research organization offering antibody sequencing, production,
and engineering services to companies and academics working in the field of antibodies.
I am giving a talk entitled,
Antibody Engineering: Beginnings to Bispecifics and Beyond.
In doing so, I will take you through the story of how
monoclonal antibodies were first discovered through to their use, now,
as highly-tailored biological therapeutics engineered
to perform in a superior way to naturally occurring antibodies.
0:36
Some of the earliest work in the field
that would go on to become immunology,
was first performed by Lady Mary Wortley Montagu and her colleagues.
She brought the concept of variolation from
the Ottoman Empire back to her homeland of Britain,
and started to use live smallpox liquid as a very crude means of vaccination.
This concept was famously taken a step further forward in 1798 by Edward Jenner.
He inoculated a small boy from a pustule of a milkmaid suffering from the mild disease,
cowpox, and injected this into the boy who then contracted the disease.
After recovering, the boy was then subjected to the same process,
but this time with a much more serious disease, smallpox.
This time the boy did not get ill as he had gained
an immunity having first being subjected to the very similar cowpox disease.
This was the start of a smallpox vaccination.
What neither Edward Jenner or Lady Montague realized at the time,
was that it was antibodies that were at the heart of the immune response.
Paul Ehrlich is arguably the father of modern immunology
and was the first person to propose a model for an antibody
which broadly speaking represents what we know to be true today.
That is, a branched molecule that binds to its target,
also known as antigen,
and is responsible for activation of the immune response,
including the complement pathway.
By 1959, Edelman and Porter were describing
the molecular structure of antibodies for
which they were jointly awarded the Nobel Prize.
Then, by 1972,
the first atomic-resolution crystal structure of an antibody fragment was published.
Interestingly, all of these achievements came
before it was possible to produce monoclonal antibodies.